Spleen tyrosine kinase/FMS-like tyrosine kinase-3 inhibition in relapsed/refractory B-cell lymphoma, including diffuse large B-cell lymphoma : updated data with mivavotinib (TAK-659/CB-659) - Gordon, Leo I. (Northwestern University Feinberg School of Medicine) ; Karmali, Reem (Northwestern University Feinberg School of Medicine) ; Kaplan, Jason B. (Northwestern University Feinberg School of Medicine) ; Popat, Rakesh (University College London) ; Burris, Howard A. (Sarah Cannon Research Institute/Tennessee Oncology) ; Ferrari, Silvia (Ospedale Papa Giovanni XXIII) ; Madan, Sumit (Banner MD Anderson Cancer Center, Gilbert, AZ 85234, USA) ; Patel, Manish R. (Florida Cancer Specialists/Sarah Cannon Research Institute) ; Gritti, Giuseppe (Ospedale Papa Giovanni XXIII) ; El-Sharkawi, Dima (Royal Marsden Hospital (Regne Unit)) ; Chau, F. Ian (Royal Marsden Hospital (Regne Unit)) ; Radford, John (University of Manchester) ; de Oteyza, Jaime Pérez (Hospital Universitario HM Sanchinarro (Madrid)) ; Zinzani, Pier Luigi (Università di Bologna) ; Iyer, Swaminathan P. (University of Texas MD Anderson Cancer Center) ; Townsend, William (University College London Hospitals) ; Miao, Harry (Takeda Development Center Americas) ; Proscurshim, Igor (Takeda Development Center Americas) ; Wang, Shining (Takeda Development Center Americas) ; Katyayan, Shilpi (Labcorp Drug Development (Estats Units d'Amèrica)) ; Yuan, Ying (Takeda Development Center Americas) ; Zhu, Jiaxi (Takeda Development Center Americas) ; Stumpo, Kate (Takeda Development Center Americas) ; Shou, Yaping (Takeda Development Center Americas) ; Carpio Segura, Cecilia del Carmen (Vall d'Hebron Institut d'Oncologia) ; Bosch José, Francesc Xavier 1947- (Universitat Autònoma de Barcelona)